Tech Company Financing Transactions
Nimbus Therapeutics Funding Round
On 10/15/2020, Nimbus Therapeutics raised $60 million in investment from BVF Partners and RA Capital.
Transaction Overview
Company Name
Announced On
10/15/2020
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds will push Nimbus' lead program, a Tyk2 inhibitor for psoriasis, into a phase 2 study, as well as a second program, a HPK1 blocker, into the clinic in 2021.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
130 Prospect St. 301
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeb Keiper
Chief Financial Officer
Holly Whittemore
Chief Scientific Officer
Peter Tummino
Vice President
Scott Edmondson
Vice President
Christine Loh
VP - Bus. Development
Abbas Kazimi
VP - Human Resources
Erin Cowhig
Browse more venture capital transactions:
Prev: 10/15/2020: Getaround venture capital transaction
Next: 10/15/2020: Plenty venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on funding rounds that are announced publicly. VC transactions on this site are derived from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs